Reports Q2 revenue $3.75M vs $2.55M last year. “This quarter’s results demonstrate the commercial strength of GIMOTI and the precision of our execution,” said Matt D’Onofrio, Chief Executive Officer of Evoke Pharma (EVOK). “With 47% year-over-year growth in net product sales and a 20% increase in new prescribers since the second quarter of last year, demand is accelerating from both physicians and patients. Fill rates are improving, and prescriber adoption is broadening across GI practices – signals that GIMOTI is becoming an essential option in the treatment of diabetic gastroparesis.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVOK:
- Evoke Pharma announces issuance of new U.S. patent for GIMOTI
- Evoke Pharma Secures New U.S. Patent for GIMOTI®
- Evoke Pharma Inc (EVOK) Q2 Earnings Cheat Sheet
- Evoke Pharma receives notice of allowance for use of GIMOTI from USPTO
- Evoke Pharma receives notice of allowance from USPTO for Gimoti patent